EBI-907
EBI-907 is an orally active and highly potent B-RafV600E inhibitor. EBI-907 demonstrates excellent A375 and Colo-205 cellular antiproliferative activity with IC50 values of 13 nM and 14 nM, respectively. EBI-907 can also cause tumor regression in a B-RafV600E-dependent Colo-205 tumor xenograft model of mice. EBI-907 is promising for research of melanoma and B-RafV600E associated cancers.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1581764-31-9
- Fòrmula: C23H21ClF2N4O3S
- Peso molecular:506.95
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
13 nM
Compound: 13g; EBI-907
|
Growth inhibition of human A375 cells
Growth inhibition of human A375 cells
|
[PMID: 26739779] |
| Calu-6 | IC50 |
455 nM
Compound: 13g; EBI-907
|
Growth inhibition of human Calu6 cells carrying a wild-type B-Raf
Growth inhibition of human Calu6 cells carrying a wild-type B-Raf
|
[PMID: 26739779] |
| COLO 205 | IC50 |
14 nM
Compound: 13g; EBI-907
|
Growth inhibition of human COLO205 cells
Growth inhibition of human COLO205 cells
|
[PMID: 26739779] |
Chemical Information
-
No. CAS 1581764-31-9
-
Peso molecular 506.95
-
Fòrmula C23H21ClF2N4O3S
-
SMILES
O=S(NC1=CC=C(C(C2=CC3=CNC4=NN=C(C5CC5)C4=C3C=C2OC)=C1Cl)F)(CCCF)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Lu B, et al. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers. Bioorg Med Chem Lett. 2016 Feb 1;26(3):819-823. [Content Brief]
[2]. Zhang J, et al. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther. 2016;17(2):199-207. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EBI-907 Related Classifications
HY-117707 Related Classifications
Powered by Bioz